Routine blood testing for "Forever Chemicals": implications of the 2022 NASEM PFAS report recommendations

John W. Downsa Division of Clinical Toxicology, Department of Emergency Medicine, Virginia Commonwealth University Health System, Richmond, VA, USACorrespondence[email protected]
View further author information

Nicholas E. Naccab Departments of Emergency Medicine and Environmental Medicine, University of Rochester Medical Center, Rochester, NY, USAView further author information

Stéphane Perronc Department of Public Health and Preventive Medicine, Université de Montréal, Montréal, Qc, CanadaView further author information

Michael G. Hollandd Department of Emergency Medicine, SUNY Upstate Medical University and the Upstate NY Poison Center, Syracuse, NY, USAView further author information

Click to increase image sizeClick to decrease image size

Disclosure statement

All authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in the paper.

Data sharing statement

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Routine blood testing for "Forever Chemicals": implications of the 2022 NASEM PFAS report recommendations

Information for

Open access

Opportunities

Help and information

Routine blood testing for "Forever Chemicals": implications of the 2022 NASEM PFAS report recommendations

Disclosure statement

Data sharing statement

Additional information

Funding

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature